	US 11,919,848 B2
	RXR agonist salt form, polymorphs thereof, and uses thereof
Vidyasagar Vuligonda, Spring, TX (US); Martin E. Sanders, Spring, TX (US); Shanming Kuang, Collegeville, PA (US); and Harsh Shailesh Shah, Monroe, NJ (US)
Assigned to Io Therapeutics, Inc., Spring, TX (US)
Filed by Io Therapeutics, Inc., Spring, TX (US)
Filed on Mar. 14, 2023, as Appl. No. 18/183,747.
Claims priority of provisional application 63/320,159, filed on Mar. 15, 2022.
Prior Publication US 2023/0295069 A1, Sep. 21, 2023
Int. Cl. C07C 51/43 (2006.01)

CPC C07C 51/43 (2013.01) [C07B 2200/13 (2013.01)]

20 Claims

1. A salt of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, which is an anhydrate, hemihydrate, monohydrate, or dihydrate of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid tris(hydroxymethyl)aminomethane.